Wallaby Treats First U.S. Patient in PIANO Aneurysm Trial
More than 20,000 patients have been treated outside the United States with the p48 and p64 MW HPC flow...
Largest Lung Nodule Study: A Breakthrough for Diagnosis
In a retrospective pooled analysis of 1,100 patients with 4–30 mm noncalcified pulmonary nodules, the Nodify CDT blood-based autoantibody...
Patient Dosing Begins in Promising Phase II LSALT Peptide Trial
No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for...
Hutchmed Starts Phase III Trial for B-Cell Lymphoma in China
A randomized, double-blind Phase II study of HMPL-760 plus R-GemOx in relapsed/refractory DLBCL reportedly improved ORR, CRR, PFS, and...
One Biomarker, Two Diseases: The p-tau Signal That Just Complicated Your Stratification Strategy
A multicenter cross-sectional study in Nature Medicine shows serum p-tau—the cornerstone of Alzheimer's blood-based diagnostics—may also detect systemic amyloidoses....
The 42% Cost Drop That Should Rewrite How We Design OUD Trials
A pattern I’ve been tracking across my patient panel for the past several months: the patients most likely to...
The FDA Doesn’t Have a GLP-1 Problem. It Has an Evidence Problem.
A trial emulation study of 174,678 type 1 diabetes patients shows GLP-1RAs cut major cardiovascular events and end-stage kidney...
Beyond Cancer UNO Trial: Early Data Suggests Safety, Activity
Seven of ten patients remained alive 19–37 months after a single intratumoral injection of ultra‑high concentration nitric oxide (UNO)...
The $30 Million Bet: CNS Investors Are Back — and Registrational Trial Design Hasn’t Kept Up
Serina Therapeutics just closed a $30 million private placement at a 68% premium to fund a registrational trial for...
Triplet Regimen, Biomarker Gate, Phase 3 Signal: What ILUSTRO’s Cohort 4 Actually Proves
Astellas's ILUSTRO trial just published Phase 2 data showing a zolbetuximab-nivolumab-mFOLFOX6 triplet in CLDN18.2-positive gastric cancer produces response rates...